Bitter pills
Source: The Hindu, 1 October 2026
Summary
- The Supreme Court criticised the gap between the price to retailer (PTR) and the maximum retail price (MRP) of some drugs, including cancer medicines. In some cases the gap is as high as 1,000%.
- The editorial says this is a regulatory design gap. Drug-price control caps the final MRP of scheduled drugs, but not the margin built into hospital transactions. It argues for a margin cap on all drugs, tapering as price rises, and says the Court is right to flag the problem.
Key facts for Prelims
- DPCO 2013 is issued under the Essential Commodities Act, 1955. NPPA (Department of Pharmaceuticals) fixes ceiling prices for Schedule-I (scheduled) formulations.
- Ceiling price formula: average PTR × (1 + 16/100). The retailer margin is 16%.
- Non-scheduled drugs: the MRP cannot rise by more than 10% in 12 months.
- PTR = price at which the manufacturer/distributor sells to the retailer or hospital. MRP = highest price chargeable to the consumer.
- The 2019 NPPA pilot capped trade margins of non-scheduled anti-cancer drugs at 30%.
- Prescription-only drugs are not available over the counter. This is why hospitals control brand choice.
- The editorial notes that the Court had earlier refused to intervene in Siddharth Dalmia (2025).
Data and details
- PTR–MRP disparity in some drugs: up to 1,000%.
- Worked example: NPPA average price ₹100 → ceiling ₹116. If the hospital negotiates a PTR of ₹50, it still sells (or bills the government) at ₹116 within the ceiling and pockets ₹66.
- 2019 proof of concept: 42 non-schedule anti-cancer drugs capped at a 30% trade margin. The Department of Pharmaceuticals said prices of 526 brands fell by up to 91%.
- Drug regulators in Karnataka and Maharashtra have flagged the financial strain on patients.
- CCI investigations established that private hospitals force patients to buy from on-premise pharmacies.
Static–dynamic linkage
The static concept is market failure in healthcare. The patient is not the buyer: the prescriber or hospital chooses the brand (information asymmetry and principal–agent problem). So competition happens for the hospital's business, not the patient's, and inflated MRPs become the "reward" for stocking a brand. The state's tools are a ceiling price for essential (scheduled) drugs and margin caps for others. Competition law is relevant too, since the editorial notes that Competition Commission investigations have found private hospitals forcing patients to use on-premise pharmacies.
Syllabus mapping: GS3 – Economy: government policies and regulation of prices; GS2 – Health: issues relating to development and management of the social sector; GS2 – Judiciary.
Background primer
Drugs (Prices Control) Order (DPCO), 2013
- What it is:
- The order under which NPPA fixes ceiling prices of drugs specified in Schedule-I.
- Why it matters:
- Make essential medicines affordable using market-derived prices. The gap is that it regulates the MRP ceiling, not the PTR-to-MRP spread.
National Pharmaceutical Pricing Authority (NPPA)
- What it is:
- The price regulator, under the Department of Pharmaceuticals (set up in 1997). It fixes ceiling prices under DPCO 2013.
- Mandate:
- It also fixes the retail price of new drugs as defined in DPCO 2013. It monitors prices of scheduled and non-scheduled formulations.
Competition Commission of India (CCI)
Additional context
-
NPPA's pilot result: The 2019 trade-margin cap of 30% on 42 non-scheduled anti-cancer medicines cut MRP of 526 brands and saved patients about ₹984 crore annually.
-
TMR also used for medical devices: NPPA has also applied Trade Margin Rationalisation to six medical devices, besides the 42 anti-cancer drugs in 2019. It invokes Paragraph 19 of DPCO 2013 (extraordinary circumstances, public interest) for this.
-
The Court's questions: A bench of Justices Vikram Nath and Sandeep Mehta advocated a uniform 16% margin on all medicines and asked the Centre to examine allegations that corporate hospitals compel patients to buy from their own or designated pharmacies.
-
Later developments (after this editorial):
- NPPA approved a 30%-of-MRP trade-margin cap for non-scheduled anti-cancer drugs on 8 October 2026. At the 12 October hearing the Centre told the Court of this decision. The Court asked why the cap could not extend to other drugs. The Centre argued that trade margins support supply of medicines to remote areas.
- On 17 October 2026 NPPA notified Trade Margin Rationalisation of 137 non-scheduled anti-cancer drugs, capping margins at 30% of MRP under Paragraph 19 of DPCO 2013. Revised prices take effect from 9 November 2026, with MRP reductions of up to 70% expected.
- On 27 October 2026 the Court reserved its order. It noted that about 90% of medicines fall outside direct price controls.
Mains dimensions
- Principal–agent distortion: Manufacturers compete for hospitals, not patients. The inflated-MRP / low-PTR design is "not technically a kickback but economically one", as the editorial puts it.
- Regulatory gap: The 2013 DPCO caps the final price of scheduled drugs, not the markup on hospital transactions. Hence ₹66 of the ₹116 ceiling in the example stays with the hospital, which can also bill state-financed schemes at the full ceiling.
- Patient outcomes: Severe financial strain, possible lower adherence to long cancer and chronic-disease regimens. Equivalent cheaper drugs lose out because they earn hospitals less.
- Evidence for reform: The 2019 pilot shows MRPs contain "compressible" margins (up to 91% price drops). This undermines the "supply-chain cost" justification.
- Design critique (editorial's own suggestion): A fixed percentage markup across all drugs is appealing, but it should be regressive (a smaller percentage as the drug price rises). Otherwise sellers still prefer costlier products.
- Institutional failure: The Union and States have not offset the absence of natural market mechanisms. The Court's intervention follows its earlier refusal to intervene in Siddharth Dalmia (2025).
- Counter-arguments (analytical): Margins support last-mile supply to remote areas (the Centre's argument, see 2b). Over-capping could hurt availability, and caps limited to one drug class may leave other drugs uncovered.
Possible Mains question
**GS2 (Health/Governance), 15 marks:** "Excessive gaps between the price to retailer and MRP of drugs reflect a regulatory gap in India's drug-price control framework. Critically examine the problem and suggest reforms."
Related topics
- National List of Essential Medicines; Essential Commodities Act, 1955
- Competition Act, 2002 and abuse of dominance / vertical arrangements
- Out-of-pocket health expenditure; Ayushman Bharat PM-JAY pricing; Jan Aushadhi and generic prescribing
- Medical devices price regulation; Universal Health Coverage
- Information asymmetry and market failure in healthcare (Economics)
Topics: GS2Economy
All current affairs of 1 October 2026 → · UPSC Current Affairs